285 related articles for article (PubMed ID: 27213343)
21. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic utility of epigenetics in breast cancer - A review.
Bhat SA; Majid S; Wani HA; Rashid S
Cancer Treat Res Commun; 2019; 19():100125. PubMed ID: 30802811
[TBL] [Abstract][Full Text] [Related]
23. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer.
Hansmann T; Pliushch G; Leubner M; Kroll P; Endt D; Gehrig A; Preisler-Adams S; Wieacker P; Haaf T
Hum Mol Genet; 2012 Nov; 21(21):4669-79. PubMed ID: 22843497
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic modifications, chromatin distribution and TP53 transcription in a model of breast cancer progression.
Santos GC; da Silva AP; Feldman L; Ventura GM; Vassetzky Y; de Moura Gallo CV
J Cell Biochem; 2015 Apr; 116(4):533-41. PubMed ID: 25358520
[TBL] [Abstract][Full Text] [Related]
25. Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.
Jones BA; Varambally S; Arend RC
Mol Cancer Ther; 2018 Mar; 17(3):591-602. PubMed ID: 29726819
[TBL] [Abstract][Full Text] [Related]
26. DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review).
Koukoura O; Spandidos DA; Daponte A; Sifakis S
Mol Med Rep; 2014 Jul; 10(1):3-9. PubMed ID: 24821107
[TBL] [Abstract][Full Text] [Related]
27. Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Wang Z; Zhang J; Zhang Y; Deng Q; Liang H
Int J Mol Med; 2018 Dec; 42(6):3542-3550. PubMed ID: 30221688
[TBL] [Abstract][Full Text] [Related]
28. MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer.
Rahman MM; Brane AC; Tollefsbol TO
Cells; 2019 Oct; 8(10):. PubMed ID: 31597272
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment.
Dworkin AM; Huang TH; Toland AE
Semin Cancer Biol; 2009 Jun; 19(3):165-71. PubMed ID: 19429480
[TBL] [Abstract][Full Text] [Related]
30. Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.
Vaclavikova R; Klajic J; Brynychova V; Elsnerova K; Alnaes GIG; Tost J; Kristensen VN; Rob L; Kodet R; Skapa P; Mrhalova M; Soucek P
Oncol Rep; 2019 Aug; 42(2):763-774. PubMed ID: 31173253
[TBL] [Abstract][Full Text] [Related]
31. Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers.
Williams LH; Choong D; Johnson SA; Campbell IG
Clin Cancer Res; 2006 Dec; 12(23):6967-72. PubMed ID: 17145815
[TBL] [Abstract][Full Text] [Related]
32. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
33. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
[TBL] [Abstract][Full Text] [Related]
34. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Rauh-Adelmann C; Lau KM; Sabeti N; Long JP; Mok SC; Ho SM
Mol Carcinog; 2000 Aug; 28(4):236-46. PubMed ID: 10972993
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation and miRNAs regulation in hereditary breast cancer: epigenetic changes, players in transcriptional and post- transcriptional regulation in hereditary breast cancer.
Pinto R; De Summa S; Pilato B; Tommasi S
Curr Mol Med; 2014 Jan; 14(1):45-57. PubMed ID: 24295492
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer.
Yeh CM; Shay J; Zeng TC; Chou JL; Huang TH; Lai HC; Chan MW
Int J Oncol; 2014 Nov; 45(5):2101-7. PubMed ID: 25175925
[TBL] [Abstract][Full Text] [Related]
37. Is TP53 dysfunction required for BRCA1-associated carcinogenesis?
Schuyer M; Berns EM
Mol Cell Endocrinol; 1999 Sep; 155(1-2):143-52. PubMed ID: 10580847
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
[TBL] [Abstract][Full Text] [Related]
39. Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.
Bai H; Cao D; Yang J; Li M; Zhang Z; Shen K
J Cell Mol Med; 2016 Apr; 20(4):581-93. PubMed ID: 26800494
[TBL] [Abstract][Full Text] [Related]
40. Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer.
Luo X; Xu J; Yu J; Yi P
Front Immunol; 2021; 12():692360. PubMed ID: 34248988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
